Cardiac risk in the treatment of breast cancer: assessment and management

References

• GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [webpage on the Internet]LyonInternational Agency for Research on Cancer2012 Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxAccessed October 10, 2014
   Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)DarbySMcGalePEffect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trialsLancet201137898041707171622019144
   PubMed Web of Science ®Google Scholar
• RechtAEdgeSBSolinLJPostmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol20011951539156911230499
   PubMed Web of Science ®Google Scholar
• EBCTCG (Early Breast Cancer Trialists’ Collaborative Group)McGalePTaylorCEffect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trialsLancet201438399352127213524656685
   PubMed Web of Science ®Google Scholar
• ClarkeMCollinsRDarbySEffects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsLancet200536695032087210616360786
   PubMed Web of Science ®Google Scholar
• HooningMJBotmaAAlemanBMLong-term risk of cardiovascular disease in 10-year survivors of breast cancerJ Natl Cancer Inst200799536537517341728
   PubMedGoogle Scholar
• BouillonKHaddyNDelalogeSLong-term cardiovascular mortality after radiotherapy for breast cancerJ Am Coll Cardiol201157444545221251585
   PubMed Web of Science ®Google Scholar
• LancellottiPNkomoVTBadanoLPExpert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of EchocardiographyEur Heart J Cardiovasc Imaging201314872174023847385
   PubMed Web of Science ®Google Scholar
• RoychoudhuriRRobinsonDPutchaVCuzickJDarbySMøllerHIncreased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based studyBMC Cancer20077917224064
   PubMed Web of Science ®Google Scholar
• DarbySCMcGalePTaylorCWPetoRLong-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registriesLancet Oncol20056855756516054566
   PubMed Web of Science ®Google Scholar
• HarrisEECorreaCHwangWTLate cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatmentJ Clin Oncol200624254100410616908933
   PubMed Web of Science ®Google Scholar
• DarbySCEwertzMMcGalePRisk of ischemic heart disease in women after radiotherapy for breast cancerN Engl J Med20133681198799823484825
   PubMed Web of Science ®Google Scholar
• TaylorCWNisbetAMcGalePDarbySCCardiac exposures in breast cancer radiotherapy: 1950s–1990sInt J Radiat Oncol Biol Phys20076951484149518035211
   PubMed Web of Science ®Google Scholar
• TaylorCWPovallJMMcGalePCardiac dose from tangential breast cancer radiotherapy in the year 2006Int J Radiat Oncol Biol Phys200872250150718374500
   PubMed Web of Science ®Google Scholar
• NilssonGHolmbergLGarmoHDistribution of coronary artery stenosis after radiation for breast cancerJ Clin Oncol201230438038622203772
   PubMed Web of Science ®Google Scholar
• CorreaCRLittHIHwangWTFerrariVASolinLJHarrisEECoronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancerJ Clin Oncol200725213031303717634481
   PubMed Web of Science ®Google Scholar
• http://www.dbcg.dk [homepage on the Internet]CopenhagenDanish Breast Cancer Cooperative Group Available from: http://www.dbcg.dkAccessed October 10, 2014
   Google Scholar
• BartlettFRYarnoldJRDonovanEMEvansPMLockeIKirbyAMMultileaf collimation cardiac shielding in breast radiotherapy: Cardiac doses are reduced, but at what cost?Clin Oncol (R Coll Radiol)2013251269069624083961
   PubMed Web of Science ®Google Scholar
• PoortmansPSHKirkoveCBudachVIrradiation of the internal mammary and medial supraclavicular lymph nodes in stage I to III breast cancer: 10 years results of the EORTC radiation oncology and breast cancer groups phase III trial 22922/10925Eur J Cancer201347Suppl 2
   Google Scholar
• WhelanTJOlivottoIAckermanINCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancerJ Clin Oncol201129LBA1003
   Web of Science ®Google Scholar
• HennequinCBossardNServagi-VernatSTen-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomyInt J Radiat Oncol Biol Phys201386586086623664327
   PubMed Web of Science ®Google Scholar
• MastMEvan Kempen-HarteveldLHeijenbrokMWLeft-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further?Radiother Oncol2013108224825324044804
   PubMed Web of Science ®Google Scholar
• ZellarsRBravoPETryggestadESPECT analysis of cardiac perfusion changes after whole-breast/chest wall radiation therapy with or without active breathing coordinator: results of a randomized phase 3 trialInt J Radiat Oncol Biol Phys201488477878524606847
   PubMed Web of Science ®Google Scholar
• OsmanSOHolSPoortmansPMEssersMVolumetric modulated arc therapy and breath-hold in image-guided locoregional left-sided breast irradiationRadiother Oncol20141121172224825176
   PubMed Web of Science ®Google Scholar
• MastMEVredeveldEJCredoeHMWhole breast proton irradiation for maximal reduction of heart dose in breast cancer patientsBreast Cancer Res Treat20141481333925266130
   PubMed Web of Science ®Google Scholar
• PrescottRJKunklerIHWilliamsLJA randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trialHealth Technol Assess20071131114917669280
   PubMed Web of Science ®Google Scholar
• KaklamaniVGGradisharWJEpirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?Clin Breast Cancer20034Suppl 1S26S3312756076
   PubMedGoogle Scholar
• SingalPKIliskovicNDoxorubicin-induced cardiomyopathyN Engl J Med19983399009059744975
   PubMed Web of Science ®Google Scholar
• LyuYLKerriganJELinCPTopoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxaneCancer Res2007678839884617875725
   PubMed Web of Science ®Google Scholar
• EwerMSLippmanSMType II chemotherapy-related cardiac dysfunction: time to recognize a new entityJ Clin Oncol2005232900290215860848
   PubMed Web of Science ®Google Scholar
• SmithLACorneliusVRPlummerCJCardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trialsBMC Cancer20101033720587042
   PubMed Web of Science ®Google Scholar
• LotrionteMBiondi-ZoccaiGAbbateAReview and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicityAm J Cardiol2013112121980198424075281
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsCancer2003972869287912767102
   PubMed Web of Science ®Google Scholar
• RybergMNielsenDSkovsgaardTHansenJJensenBVDombernowskyPEpirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancerJ Clin Oncol199816350235089817267
   PubMed Web of Science ®Google Scholar
• MinottiGLicataSSaponieroAAnthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metaboliteChem Res Toxicol2000131336134111123976
   PubMed Web of Science ®Google Scholar
• RybergMNielsenDCorteseGNielsenGSkovsgaardTAndersenPKNew insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patientsJ Natl Cancer Inst20081001058106718664656
   PubMed Web of Science ®Google Scholar
• van DalenECvan der PalHJCaronHNKremerLCDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyCochrane Database Syst Rev20064CD00500817054232
   PubMedGoogle Scholar
• GiottaFLorussoVMaielloELiposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric studyAnn Oncol200718Suppl 6vi66vi6917591836
   PubMed Web of Science ®Google Scholar
• BrainEGMertensCGirreVImpact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trialCrit Rev Oncol Hematol201180116017021035352
   PubMed Web of Science ®Google Scholar
• RaysonDSuterTMJackischCCardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trialAnn Oncol20122371780178822056854
   PubMed Web of Science ®Google Scholar
• JooKIXiaoLLiuSCrosslinked multilamellar liposomes for controlled delivery of anticancer drugsBiomaterials201334123098310923375392
   PubMed Web of Science ®Google Scholar
• LiuYFangJKimYJWongMKWangPCodelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activityMol Pharm20141151651166124673622
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)PetoRDaviesCComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
   PubMed Web of Science ®Google Scholar
• RowinskyEKMcGuireWPGuarnieriTFishermanJSChristianMCDonehowerRCCardiac disturbances during the administration of taxolJ Clin Oncol19919170417121678781
   PubMed Web of Science ®Google Scholar
• ShimoyamaMMurataYSumiKIHamazoeRKomuroIDocetaxel induced cardiotoxicityHeart200186221911454849
   PubMed Web of Science ®Google Scholar
• ArbuckSGStraussHRowinskyEA reassessment of cardiac toxicity associated with TaxolJ Natl Cancer Inst Monogr1993151171307912518
   PubMedGoogle Scholar
• GianniLSalvatorelliEMinottiGAnthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanesCardiovasc Toxicol20077677117652806
   PubMed Web of Science ®Google Scholar
• GiordanoSHBooserDJMurrayJLA detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancerClin Cancer Res200283360336812429622
   PubMed Web of Science ®Google Scholar
• GennariASalvadoriBDonatiSCardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factorsJ Clin Oncol1999173596360210550159
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKCabidduMLonatiVBarniSMortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysisBreast Cancer Res Treat2012135233534622689092
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• Breast International Group (BIG) 1-98 Collaborative GroupThürlimannBKeshaviahAA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• CoombesRCKilburnLSSnowdonCFSurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialLancet2007369956155957017307102
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet20053659453606215639680
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMAromatase inhibitors in breast cancerN Engl J Med2003348242431244212802030
   PubMed Web of Science ®Google Scholar
• LinCChenLSKuoSJChenDRAdjuvant tamoxifen influences the lipid profile in breast cancer patientsBreast Care (Basel)201491353924803885
   PubMed Web of Science ®Google Scholar
• BraithwaiteRSChlebowskiRTLauJGeorgeSHessRColNFMeta-analysis of vascular and neoplastic events associated with tamoxifenJ Gen Intern Med2003181193794714687281
   PubMed Web of Science ®Google Scholar
• Arimidex, Tamoxifen, Alone or in Combination Trialists’ GroupBuzdarAHowellAComprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trialLancet Oncol20067863364616887480
   PubMed Web of Science ®Google Scholar
• MouridsenHKeshaviahACoatesASCardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trialJ Clin Oncol200725365715572217998546
   PubMed Web of Science ®Google Scholar
• BlissJMKilburnLSColemanREDisease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJ Clin Oncol201230770971722042946
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17J Natl Cancer Inst200597171262127116145047
   PubMed Web of Science ®Google Scholar
• DawoodSBroglioKBuzdarAUHortobagyiGNGiordanoSHPrognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based reviewJ Clin Oncol2010281929819933921
   PubMed Web of Science ®Google Scholar
• VianiGAAfonsoSLStefanoEJDe FendiLISoaresFVAdjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trialsBMC Cancer2007715317686164
   PubMed Web of Science ®Google Scholar
• SeidmanAHudisCPierriMKCardiac dysfunction in the trastuzumab clinical trials experienceJ Clin Oncol20022051215122111870163
   PubMed Web of Science ®Google Scholar
• OnitiloAAEngelJMStankowskiRVCardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factorsTher Adv Drug Saf20145415416625083270
   PubMedGoogle Scholar
• MojaLTagliabueLBalduzziSTrastuzumab containing regimens for early breast cancerCochrane Database Syst Rev20124CD00624322513938
   PubMed Web of Science ®Google Scholar
• BowlesEJWellmanRFeigelsonHSRisk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort studyJ Natl Cancer Inst2012104171293130522949432
   PubMedGoogle Scholar
• NaumannDRusiusVMargiottaCFactors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancerAnticancer Res20133341717172023564821
   PubMed Web of Science ®Google Scholar
• ZhaoYYSawyerDRBaligaRRNeuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytesJ Biol Chem19982731710261102699553078
   PubMed Web of Science ®Google Scholar
• De KeulenaerGWDoggenKLemmensKThe vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted erbb2 anticancer therapyCirc Res20101061354620056944
   PubMed Web of Science ®Google Scholar
• FarolfiAMelegariEAquilinaMTrastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factorsHeart201399963463923349345
   PubMed Web of Science ®Google Scholar
• RussoGCioffiGDi LenardaARole of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancerIntern Emerg Med20127543944622714882
   PubMed Web of Science ®Google Scholar
• CochetAQuilichiniGDygai-CochetIBaseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancerBreast Cancer Res Treat2011130384585421918836
   PubMed Web of Science ®Google Scholar
• ValachisAMauriDPolyzosNPChlouverakisGMavroudisDGeorgouliasVTrastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysisBreast201120648549021784637
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHickishTPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Ann Oncol20132492278228423704196
   PubMed Web of Science ®Google Scholar
• BuzdarAUSumanVJMeric-BernstamFFluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialLancet Oncol201314131317132524239210
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol20082681231123818250349
   PubMed Web of Science ®Google Scholar
• ChenJLongJBHurriaAOwusuCSteingartRMGrossCPIncidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancerJ Am Coll Cardiol201260242504251223158536
   PubMed Web of Science ®Google Scholar
• SerranoCCortésJDe Mattos-ArrudaLTrastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factorsAnn Oncol201223489790221828361
   PubMed Web of Science ®Google Scholar
• BeauclairSFormentoPFischelJLRole of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicityAnn Oncol20071881335134117693647
   PubMed Web of Science ®Google Scholar
• LemieuxJDiorioCCôtéMAAlcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumabAnticancer Res20133362569257623749910
   PubMed Web of Science ®Google Scholar
• RocaLDiérasVRochéHCorrelation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trialBreast Cancer Res Treat2013139378980023780683
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med20063552733274317192538
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med201236610911922149875
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• ValachisANearchouALindPMauriDLapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidenceBreast Cancer Res Treat2012135365566222875745
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMOverall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyJ Clin Oncol201230212585259222689807
   PubMed Web of Science ®Google Scholar
• ValachisANearchouAPolyzosNPLindPCardiac toxicity in breast cancer patients treated with dual HER2 blockadeInt J Cancer201313392245225223629633
   PubMed Web of Science ®Google Scholar
• CuriglianoGCardinaleDSuterTCardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnn Oncol201223Suppl 7vii155vii16622997448
   PubMed Web of Science ®Google Scholar
• PlanaJCGalderisiMBaracAExpert consensus for multi-modality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular ImagingEur Heart J Cardiovasc Imaging201415101063109325239940
   PubMed Web of Science ®Google Scholar
• FloydJMorganJPCardiotoxicity of anthracycline-like chemotherapy agentsUpToDateSavareseDFMUpToDateWaltham, MAAccessed on September 8, 2014
   Google Scholar
• PerezEAMorganJPCardiotoxicity of trastuzumab and other HER2-targeted agentsUpToDateSavareseDFMUpToDateWaltham, MAAccessed on September 15, 2014
   Google Scholar
• MarksLBConstineLSJacob AdamsMCardiotoxicity of radiation therapy for malignancyUpToDateRossMEUpToDateWaltham, MAAccessed on September 1, 2014
   Google Scholar
• RomondEHJeongJHRastogiPSeven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol201230313792379922987084
   PubMed Web of Science ®Google Scholar
• AltenaRPerikPJvan VeldhuisenDJde VriesEGGietemaJACardiovascular toxicity caused by cancer treatment: strategies for early detectionLancet Oncol200910439139919341970
   PubMed Web of Science ®Google Scholar
• EwerMSAliMKMackayBA comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving AdriamycinJ Clin Oncol1984221121176699662
   PubMed Web of Science ®Google Scholar
• JensenBVSkovsgaardTNielsenSLFunctional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patientsAnn Oncol200213569970912075737
   PubMed Web of Science ®Google Scholar
• EwerMSLenihanDJLeft ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?J Clin Oncol20082681201120318227525
   PubMed Web of Science ®Google Scholar
• ThavendiranathanPGrantADNegishiTPlanaJCPopovićZBMarwickTHReproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapyJ Am Coll Cardiol2013611778423199515
   PubMed Web of Science ®Google Scholar
• LangRMMor-AviVDentJMKramerCMThree-dimensional echocardiography: is it ready for everyday clinical use?JACC Cardiovasc Imaging20092111411719356542
   PubMed Web of Science ®Google Scholar
• LorenziniCCorsiCAquilinaMEarly detection of cardiotoxicity in chemotherapy-treated patients from real-time 3D echocardiographyComputing in Cardiology Conference (CinC)2013249252
   Google Scholar
• JurcutRWildiersHGanameJStrain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancerJ Am Soc Echocardiogr200821121283128919041569
   PubMed Web of Science ®Google Scholar
• HareJLBrownJKLeanoRJenkinsCWoodwardNMarwickTHUse of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumabAm Heart J2009158229430119619708
   PubMed Web of Science ®Google Scholar
• Fallah-RadNWalkerJRWassefAThe utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapyJ Am Coll Cardiol201157222263227021616287
   PubMed Web of Science ®Google Scholar
• ErvenKJurcutRWeltensCAcute radiation effects on cardiac function detected by strain rate imaging in breast cancer patientsInt J Radiat Oncol Biol Phys20117951444145120605341
   PubMed Web of Science ®Google Scholar
• KavousiMElias-SmaleSRuttenJHEvaluation of newer risk markers for coronary heart disease risk classification: a cohort studyAnn Intern Med2012156643844422431676
   PubMed Web of Science ®Google Scholar
• ThavendiranathanPWinterspergerBJFlammSDMarwickTHCardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic reviewCirc Cardiovasc Imaging2013661080109124254478
   PubMed Web of Science ®Google Scholar
• CardinaleDSandriMTColomboAPrognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapyCirculation2004109222749275415148277
   PubMed Web of Science ®Google Scholar
• SawayaHSebagIAPlanaJCEarly detection and prediction of cardiotoxicity in chemotherapy-treated patientsAm J Cardiol201110791375138021371685
   PubMed Web of Science ®Google Scholar
• CardinaleDColomboATorrisiRTrastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluationJ Clin Oncol201028253910391620679614
   PubMed Web of Science ®Google Scholar
• SawayaHSebagIAPlanaJCAssessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumabCirc Cardiovasc Imaging20125559660322744937
   PubMed Web of Science ®Google Scholar
• KuttehLAHobdayTJaffeAA correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancerJ Clin Oncol20072518S57917242396
   PubMedGoogle Scholar
• RadererMKornekGWeinländerGKastnerJSerum troponin T levels in adults undergoing anthracycline therapyJ Natl Cancer Inst19978921718998187
   PubMedGoogle Scholar
• LenihanDJMasseyMRBaysingerKBSuperior Detection of Cardiotoxicity during Chemotherapy Using BiomarkersJ Card Fail200713S151
   Google Scholar
• RomanoSFratiniSRicevutoESerial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patientsBr J Cancer2011105111663166822068815
   PubMed Web of Science ®Google Scholar
• SkovgaardDHasbakPKjaerABNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculographyPLoS One201495e9673624800827
   PubMed Web of Science ®Google Scholar
• DodosFHalbsguthTErdmannEHoppeUCUsefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adultsClin Res Cardiol200897531832618193371
   PubMed Web of Science ®Google Scholar
• KnoblochKTepeJLichtinghagenRLuckHJVogtPMMonitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptideClin Med200771888917348585
   PubMed Web of Science ®Google Scholar
• KnoblochKTepeJRossnerDCombined NT-pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapyInt J Cardiol2008128331632517707098
   PubMed Web of Science ®Google Scholar
• DamrotJNubelTEpeBRoosWPKainaBFritzGLovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposideBr J Pharmacol2006149898899717088865
   PubMed Web of Science ®Google Scholar
• RanXZRanXZongZWProtective effect of atorvastatin on radiation-induced vascular endothelial cell injury in vitroJ Radiat Res201051552753320921821
   PubMed Web of Science ®Google Scholar
• SeiceanSSeiceanAPlanaJCBuddGTMarwickTHEffect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort studyJ Am Coll Cardiol201260232384239023141499
   PubMed Web of Science ®Google Scholar
• AcarZKaleATurgutMEfficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathyJ Am Coll Cardiol201158998898921851890
   PubMed Web of Science ®Google Scholar
• AsanumaHMinaminoTSanadaSBeta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine heartsCirculation2004109222773277915148268
   PubMed Web of Science ®Google Scholar
• KimIMTilleyDGChenJBeta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivationProc Natl Acad Sci U S A200810538145551456018787115
   PubMed Web of Science ®Google Scholar
• KayaMGOzkanMGunebakmazOProtective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control studyInt J Cardiol201316752306231022727976
   PubMed Web of Science ®Google Scholar
• KalayNBasarEOzdogruIProtective effects of carvedilol against anthracycline-induced cardiomyopathyJ Am Coll Cardiol200648112258226217161256
   PubMed Web of Science ®Google Scholar
• BoschXRoviraMSitgesMEnalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)J Am Coll Cardiol201361232355236223583763
   PubMed Web of Science ®Google Scholar
• EwerMSVooletichMTDurandJBReversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatmentJ Clin Oncol200523317820782616258084
   PubMed Web of Science ®Google Scholar
• OlivaSCioffiGFrattiniSItalian Cardio-Oncological NetworkAdministration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?Oncologist201217791792422673631
   PubMed Web of Science ®Google Scholar
• TokudomeTMizushigeKNomaTPrevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometryJ Cardiovasc Pharmacol200036336136810975594
   PubMed Web of Science ®Google Scholar
• Abd El-AzizMAOthmanAIAmerMEl-MissiryMAPotential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in ratsJ Appl Toxicol200121646947311746193
   PubMed Web of Science ®Google Scholar
• LemmensKSegersVFDemolderMDe KeulenaerGWRole of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte crosstalkJ Biol Chem200628128194691947716698793
   PubMed Web of Science ®Google Scholar
• NakamaeHTsumuraKTeradaYNotable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisoloneCancer2005104112492249816247790
   PubMed Web of Science ®Google Scholar
• DessìMMadedduCPirasALong-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rateSpringerplus20132119823741643
   PubMed Web of Science ®Google Scholar
• CardinaleDColomboASandriMTPrevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibitionCirculation2006114232474248117101852
   PubMed Web of Science ®Google Scholar
• TofieldAACE inhibitor reduces radiation injury to myocardiumEur Heart J201334272023202424015406
   PubMed Web of Science ®Google Scholar
• ScottJMKhakooAMackeyJRHaykowskyMJDouglasPSJonesLWModulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanismsCirculation2011124564265021810673
   PubMed Web of Science ®Google Scholar
• HaykowskyMJMackeyJRThompsonRBJonesLWPatersonDIAdjuvant trastuzumab induces ventricular remodeling despite aerobic exercise trainingClin Cancer Res200915154963496719622583
   PubMed Web of Science ®Google Scholar
• HuntSAAbrahamWTChinMH2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung TransplantationJ Am Coll Cardiol20095315e1e9019358937
   PubMed Web of Science ®Google Scholar
• CardinaleDColomboALamantiaGAnthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapyJ Am Coll Cardiol201055321322020117401
   PubMed Web of Science ®Google Scholar
• TocchettiCGRagoneGCoppolaCDetection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challengeEur J Heart Fail201214213013722219501
   PubMed Web of Science ®Google Scholar
• SuterTMProcterMvan VeldhuisenDJTrastuzumab-associated cardiac adverse effects in the herceptin adjuvant trialJ Clin Oncol200725253859386517646669
   PubMed Web of Science ®Google Scholar
• MackeyJRClemonsMCotéMACardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working GroupCurr Oncol2008151243518317582
   PubMed Web of Science ®Google Scholar